New drug aims to stop EBV in kidney transplants
NCT ID NCT07368153
First seen Jun 24, 2026 · Last updated Aug 26, 2026 · Updated 4 times
Summary
This study tests whether an IDO-1 inhibitor can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant recipients who have never had EBV but receive a kidney from an EBV-positive donor. Nine participants will receive either the drug or a placebo for 28 days, alongside standard care, and be monitored for side effects and viral changes. The goal is to see if the drug is safe and tolerable.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- IDO-1 inhibitor
- What this could lead to
- If it works, this could help prevent serious EBV-related complications in kidney transplant patients who are at risk.
- What could go wrong
- This is a very small early-phase trial with only 9 participants, so results may not apply broadly. The drug may cause side effects or fail to prevent EBV infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 9 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Willing and able to provide informed consent 2. Male or female aged ≥18 years 3. EBV seronegative at the time of renal transplant 4. If women of child-bearing potential (WOCBP), participants must have a negative serum pregnancy test at screening and inclusion, and must be willing to use a highly effective method of birth control for the duration of the study. Acceptable methods of contraception: 1. Hormonal contraception associated with inhibition of ovulation 2. Intrauterine device (IUD) 3. Intrauterine hormone-releasing system (IUS) 4. Bilateral tubal occlusion 5. Vasectomised partner 6. Condom with spermicide 7. Sexual abstinence, in line with the preferred and usual lifestyle of the participant. Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 5. If male, participants must be prepared to use reliable barrier method contraception and a second method such as spermicide for the duration of the study unless surgically sterile. Exclusion Criteria: 1. EBV seropositivity at the time of transplant 2. Participants with any form of cancer within the last 12 months, or patients continuing to receive chemo or immunotherapy within the last 12 months. 3. Participants with a history of PTLD 4. Other active systemic infections requiring treatment prior to and at the time of baseline. Prophylactic agents are permitted. 5. CYP3A4 and CYP2C28 Inhibitors and Inducers (List may be found in Appendix 1) 6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3 x ULN 7. Any condition for which, in the opinion of the investigator, the treatment or participation in the study may pose a health risk to the participant 8. Planned or active participation in any other study with an investigational medicinal product (IMP). 9. Have taken an IMP within the last 3 months. 10. Unwilling or unable to provide fully informed consent. 11. Unwilling or unable to comply with study procedures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre hospitalier universitaire vaudois (CHUV)
NOT_YET_RECRUITINGLausanne, Lausanne, 1011, Switzerland
-
University Hospital Basel
NOT_YET_RECRUITINGBasel, 4031, Switzerland
-
University Hospital Bern
RECRUITINGBern, Canton of Bern, 3010, Switzerland
-
University Hospital Zurich
NOT_YET_RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New fluid aims to keep donated kidneys healthier
- Can a phone app and a coach keep a new kidney healthier?
- A new tool aims to predict and prevent living kidney donor Drop-Out
- Can digital tools and training help more kidney patients get transplants?
- Can a new preservation fluid keep donor kidneys healthier for transplant?
- Oxygen bath for donor kidneys: a new hope for transplant success?